Home/Karamedica/Samuel Hudson, PhD

SH

Samuel Hudson, PhD

Chief Scientific Officer

Therapeutic Areas

Surgical Hemostasis Oncology Neurology

Karamedica Pipeline

Drug	Indication	Phase
Implantable Hemostatic Device	Intraoperative Bleeding Control	Pre-clinical
Chitosan Drug Delivery Vehicle	Superficial Bladder Cancer	Pre-clinical

Leadership Team at Karamedica

Andrew Crofton, PhD

Chief Executive Officer

Taub T Swartz, MBA

Chief Financial Officer

Eric Gosink, PhD

Senior Vice President – Corporate Strategy

View full Karamedica profile